Anticancer agent 242
Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) [1].
Product Specifications
CAS Number
[9007-83-4]
UNSPSC
12352005
Target
Biochemical Assay Reagents
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-242.html
Smiles
FC1=C(F)C(SCCC2=CC=C(C(N3CCN(C(C4=CC=CC=C4C5=C(C=C/6)C(OC7=C5C=CC(N(CC)CC)=C7)=CC6=[N+](CC)\CC)=O)CC3)=O)C=C2)=C(F)C(NC8CCCCCCCCCCC8)=C1S(=O)(N)=O.[Cl-]
Molecular Formula
C59H72ClF3N6O5S2
Molecular Weight
1101.82
References & Citations
[1]Niels V Heise, et al. Dehydroabietylamine-substituted trifluorobenzene sulfonamide rhodamine B hybrids as anticancer agents overcoming drug resistance. Eur J Med Chem. 2024 Jul 10:276:116667.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
